[1]胡欣 陈国芳 刘超.男性迟发型性腺功能减退症的诊断与治疗[J].国际内分泌代谢杂志,2015,(01):59-62.[doi:10.3760/cma.j.issn.1673-4157.2015.01.015]
　Hu Xin,Chen Guofang,Liu Chao..Diagnosis and therapeutic options for late-onset hypogonadism in men[J].International Journal of Endocrinology and Metabolism,2015,(01):59-62.[doi:10.3760/cma.j.issn.1673-4157.2015.01.015]
点击复制

男性迟发型性腺功能减退症的诊断与治疗()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
期数:
2015年01
页码:
59-62
栏目:
综述
出版日期:
2015-01-20

文章信息/Info

Title:
Diagnosis and therapeutic options for late-onset hypogonadism in men
作者:
胡欣 陈国芳 刘超
210028 南京,中国中医科学院江苏分院,南京中医药大学附属中西医结合医院内分泌代谢病院区
Author(s):
Hu Xin; Chen Guofang; Liu Chao.
Endocrine and Diabetes Center, Jiangsu Province Hospital on Integration of Chinese and Western Medicine, Nanjing University of Traditional Chinese Medicine, Jiangsu Branch of China Academy of Chinese Medical Science, Nanjing 210028, ChinaCorresponding author: Liu Chao, Email: liuchao@jsatcm.com
关键词:
迟发型性腺功能减退症;  诊断;  治疗
Keywords:
Late-onset hypogonadism;  Diagnosis;  Therapy
DOI:
10.3760/cma.j.issn.1673-4157.2015.01.015
摘要:
近年来,男性迟发型性腺功能减退症(LOH)成为全球研究的热点。对勃起功能障碍、下丘脑/垂体病变、肥胖、代谢综合征、2型糖尿病、人类免疫缺陷病毒感染者等高危人群,应进行LOH筛查,若出现3种或3种以上性功能减退症状,且伴随血清总睾酮<11 nmol/L及游离睾酮<225 pmol/L,可诊断为LOH。LOH主要依赖药物治疗,尤其是雄激素制剂。对于LOH合并肥胖、2型糖尿病、代谢综合征的患者,提倡生活方式干预。对有生育需求的患者,可考虑促性腺激素或促性腺激素释放激素的脉冲式治疗。对无生育要求的患者,睾酮替代是治疗LOH的金标准。
Abstract:
In the past few years, late-onset hypogonadism(LOH)in men has been extensively studied. Subjects with erectile dysfunction, hypothalamic/pituitary diseases, obesity, metabolic syndrome, type 2 diabetes mellitus(T2DM),human immunodeficiency virus infection should evaluate LOH. The presence of at least three hypogonadism symptoms along with a reduced testosterone level(less than 11 nmol/L)and a decreased free testosterone level(less than 225 pmol/L)is considered as the minimum criteria for the diagnosis of LOH. Drug therapy, especially androgenic hormone, is mainly used in the treatment of LOH. Lifestyle modification should be strongly encouraged in hypogonadal subjects with obesity, T2DM and metabolic syndrome. Gonadotropin or pulsatile gonadotropin releasing hormone maybe recommended for those with the need of fertility, where as testosterone replacement therapy is the golden treatment for those without.

参考文献/References:

[1] Wang C, Nieschlag E, Swerdloff R, et al. International Society of Andrology(ISA); International Society for the Study of Aging Male(ISSAM); European Association of Urology(EAU); European Academy of Andrology(EAA); American Society of Andrology(ASA). Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA Recommendations[J]. J Androl, 2009, 30(1): 1-9.
[2] Tajar A, Forti G, O’Neill TW, et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men:evidence from the European Male Ageing Study[J]. J Clin Endocrinol Metab, 2010, 95(4): 1810-1818.
[3] Araujo AB, Wittert GA. Endocinology of the aging male[J]. Best Pract Res Clin Endocrinol Metab,2011, 25(2): 303-319.
[4] 吴旻, 李建辉, 于晓华, 等. 浙江省一农村社区迟发性性腺功能减退症的调查研究[J].中华男科学杂志, 2013,19(6): 522-526.
[5] 孙凯, 梁国庆, 陈向锋, 等. 上海市社区中老年男性迟发性性腺功能减退流行病学调查和研究∥中华医学会男科学分会第十三次全国男科学术会议论文集,郑州,2012[C].北京:《中华医学杂志》社有限责任公司,2012:1.
[6] Wu FC, von Eckardstein A. Androgens and coronary artery disease[J]. Endocr Rev, 2003, 24(2): 183-217.
[7] Seidman SN.Testosterone deficiency and mood in aging men:pathogenic and therapeutic interactions[J].World J Biol Psychiatry,2003,4(1):14-20.
[8] Bhasin S, Cunningham GR, Hayes FJ, et al. Task Force, Endocrine Society. Testosterone therapy in men with androgen de ciency syndromes: an Endocrine Society clinical practice guideline[J]. J Clin Endocrinol Metab, 2010, 95(6): 2536-2559.
[9] Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men[J].New Engl J Med, 2010,363(2): 123-135.
[10] Corona G, Rastrelli G, Forti G, et al. Update in testosterone therapy for men[J]. J Sex Med, 2011, 8(3): 639-654.
[11] Huhtaniemi I, Forti G. Male late-onset hypogonadism: pathogenesis, diagnosis and treatment[J].Nat Rev Urol, 2011, 8(6): 335-344.
[12] Corona G, Rastrelli G, Vignozzi L, et al. Emerging medication for the treatment of male hypogonadism[J]. Expert Opin Emerg Drugs, 2012, 17(2): 239-259.
[13] Wu FC, Tajar A, Pye SR, et al. European Male Aging Study Group. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modi able risk factors:the European Male Aging Study[J].J Clin Endocrinol Metab, 2008, 93(7): 2737-2745.
[14] Corona G, Monami M, Rastrelli G, et al. Type 2 diabetes mellitus and testosterone: a meta-analysis study[J].Int J Androl, 2011, 34(6 pt 1): 528-540.
[15] Heufelder AE, Saad F, Bunck MC, et al. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone[J].J Androl, 2009, 30(6): 726-733.
[16] Hoyos CM, Yee BJ, Phillips CL, et al. Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: a randomised placebo-controlled trial[J].Eur J Endocrinol, 2012, 167(4): 531-541.
[17] Corona G, Rastrelli G, Monami M, et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism:a systematic review and meta-analysis[J].Eur J Endocrinol, 2013, 168(6): 829-843.
[18] Luconi M, Samavat J, Seghieri G, et al. Determinants of testosterone recovery after bariatric surgery: is it only a matter of reduction of body mass index?[J].Fertil Steril, 2013, 99(7): 1872-1879.
[19] Katz DJ, Nabulsi O, Tal R, et al. Outcomes of clomiphene citrate treatment in young hypogonadal men[J].BJU Int,2012,110(4): 573-578.
[20] Ribeiro RS, Abucham J. Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment[J].Eur J Endocrinol, 2009,161(1): 163-169.

相似文献/References:

[1]孙敏讷,段宇.老年亚临床甲状腺功能减退症的诊治特点[J].国际内分泌代谢杂志,2014,(06):411.[doi:10.3760/cma.j.issn.1673-4157.2014.06.014]
　Sun Minne,Duan Yu..Diagnositc and therapeutic characteristics of subclinical hypothyroidism in elderly people[J].International Journal of Endocrinology and Metabolism,2014,(01):411.[doi:10.3760/cma.j.issn.1673-4157.2014.06.014]
[2]刘晓蓉 朱德发.糖尿病下肢动脉病变的诊断与治疗[J].国际内分泌代谢杂志,2015,(05):327.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.010]
　Liu Xiaorong*,Zhu Defa..Diagnosis and treatment of lower extremity arterial disease in diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(01):327.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.010]
[3]曹琳,刘超.妊娠糖尿病诊疗的争议与共识[J].国际内分泌代谢杂志,2016,36(03):176.[doi:10.3760/cma.j.issn.1673-4157.2016.03.08]
　Cao Lin,Liu Chao..Controversy and concensus on the diagnosis and treatment of gestational diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2016,36(01):176.[doi:10.3760/cma.j.issn.1673-4157.2016.03.08]
[4]毛斐,鹿斌,李益明.SUDOSCAN对糖尿病周围神经病变的诊断价值[J].国际内分泌代谢杂志,2016,36(05):331.[doi:10.3760/cma.j.issn.1673-4157.2016.05.12]
　Mao Fei,Lu Bin,Li Yiming.Diagnostic value of SUDOSCAN in detecting diabetic peripheral neuropathy[J].International Journal of Endocrinology and Metabolism,2016,36(01):331.[doi:10.3760/cma.j.issn.1673-4157.2016.05.12]
[5]郑仁东,刘超.糖尿病合并男性性腺功能减退症的识别与处理[J].国际内分泌代谢杂志,2016,36(06):394.[doi:10.3760/cma.j.issn.1673-4157.2016.06.09]
　Zheng Rendong,Liu Chao..Recognition and treatment of diabetes with male hypogonadism[J].International Journal of Endocrinology and Metabolism,2016,36(01):394.[doi:10.3760/cma.j.issn.1673-4157.2016.06.09]
[6]刘颖丰,刘芳.角膜共聚焦显微镜对糖尿病周围神经病变的诊断价值[J].国际内分泌代谢杂志,2017,37(03):178.[doi:10.3760/cma.j.issn.1673-4157.2017.03.009]
　Liu Yingfeng,Liu Fang..Diagnostic value of corneal confocal microscopy on diabetic peripheral neuropathy[J].International Journal of Endocrinology and Metabolism,2017,37(01):178.[doi:10.3760/cma.j.issn.1673-4157.2017.03.009]
[7]曹白露,邵加庆.SUDOSCAN在糖尿病微血管并发症早期诊断 及治疗评估中的作用[J].国际内分泌代谢杂志,2017,37(06):401.
　Cao Bailu,Shao Jiaqing..The value of SUDOSCAN in the early diagnosis and evaluation of diabetic microvascular complications[J].International Journal of Endocrinology and Metabolism,2017,37(01):401.
[8]赵万霞 王何婷 任月秋 崔景秋.糖尿病肾病早期标志物研究新进展[J].国际内分泌代谢杂志,2018,38(03):192.[doi:10.3760/cma.j.issn.1673-4157.2018.03.012]
　Zhao Wanxia*,Wang Heting,Ren Yueqiu,et al.Recent progress on the study of early marker for diabetic nephrophy[J].International Journal of Endocrinology and Metabolism,2018,38(01):192.[doi:10.3760/cma.j.issn.1673-4157.2018.03.012]
[9]邹梦晨 胡萍 罗祥蓉 蒋娅 高方 曹瑛.糖尿病足骨髓炎的诊疗进展[J].国际内分泌代谢杂志,2018,38(04):257.[doi:10.3760/cma.j.issn.1673-4157.2018.04.010]
　Zou Mengchen,Hu Ping,Luo Xiangrong,et al.Diagnosis and treatment of diabetic foot osteomyelitis[J].International Journal of Endocrinology and Metabolism,2018,38(01):257.[doi:10.3760/cma.j.issn.1673-4157.2018.04.010]
[10]胡咏新 郑仁东 刘洲君 刘超.2017年骨质疏松年度进展[J].国际内分泌代谢杂志,2018,38(06):423.[doi:10.3760/cma.j.issn.1673-4157.2018.06.016]
　Hu Yongxin,Zheng Rendong,Liu Zhoujun,et al.Annual development of osteoporosis in 2017[J].International Journal of Endocrinology and Metabolism,2018,38(01):423.[doi:10.3760/cma.j.issn.1673-4157.2018.06.016]

备注/Memo

备注/Memo:
通信作者:刘超,Email: liuchao@jsatcma.com
更新日期/Last Update: 2015-01-20